ZEPZELCA ® (LURBINECTEDIN) IN COMBINATION WITH ATEZOLIZUMAB APPROVED AS FIRTS-LINE MAINTENANCE THERAPY FORMA EXTENSIVE-STAGE SMALL CELL LUNG CANCER IN KUWAIT .

KUWAIT MANTIENE LA PROHIBICIÓN DE OTORGAR PERMISOS DE RESIDENCIA A EXTRANJEROS QUE PADEZCAN CÁNCER .

 ESTA RESTRICTIVA NORMATIVA ENTRÓ EN VIGOR EN EL AÑO 2018 Y SE MANTIENE PLENAMENTE VIGENTE , HABIÉNDOSE REFORZADO LOS CONTROLES MÉDICOS FRONTERIZOS A TRAVÉS DE REFORMAS del SISTEMA DE SALUD Y DE INMIGRACIÓN .

Además del cáncer, la prohibición se extiende a otras enfermedades como la diabetes, o tensión alta, insuficiencia renal, enfermedades diarreicas o problemas de visión .

" TODO PARA REDUCIR COSTES EN LA ATENCIÓN SANITARIA PARA LOS NO KUWAITÍES " .

Así, el país árabe se convierte en el primer país en rechazar que enfermos no nacionales vivan en su territorio .

Además de ahorrar en gastos, la medida, hecha ley, busca que los que quieran residir en el país sean aptos para trabajar y no supongan una carga para el Estado .

Stockholm, Sweden, September 4, 2026 .

 Immedica announces that Zepzelca® (lurbinectedin) in combination with atezolizumab (Tecentriq®) has been approved as a maintenance treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first-line induction therapy with atezolizumab, carboplatin and etoposide in Kuwait.

“This approval represents another step forward in our efforts to make innovative treatment options available to patients with extensive-stage small cell lung cancer in the Middle East. We are pleased to support continued access to Zepzelca in Kuwait and to contribute to addressing the significant unmet need in this aggressive disease,” said Ashraf Attia, General Manager for the MENA region.

The approval is based on results from the Phase 3 IMforte trial, which showed that the lurbinectedin and atezolizumab combination reduced the risk of disease progression or death by 46% and the risk of death by 27%, compared to atezolizumab maintenance therapy alone. Following four cycles of induction therapy, from the point of randomization the median overall survival (OS) for the combination regimen was 13.2 months versus 10.6 months (stratified hazard ratio [HR]=0.73; 95% CI: 0.57–0.95; p=0.0174). From the point of randomization, median progression-free survival (PFS) by independent assessment was 5.4 months versus 2.1 months, respectively (stratified HR=0.54, 95% CI: 0.43–0.67; p<0.0001). Safety was consistent with the known safety profiles of both treatments. The results were presented at the 2025 American Society of Clinical Oncology (ASCO) annual meeting and simultaneously published in The Lancet.

Immedica has a strategic partnership with PharmaMar, where Immedica holds the distribution rights to Zepzelca in the Nordics, the UK & Ireland, Central Eastern Europe as well as in the Middle East and North Africa.